Ezetimibe
Residual CVD risk varies; individualized treatments best to combat it
BOSTON — The medical community is better equipped to combat residual CVD risk than previously, but prevention of residual risk should be tailored using a precision medicine approach, a speaker said at the Cardiometabolic Health Congress.
Familial hypercholesterolemia in 9% of young adults with ACS; many undertreated afterward
Among younger patients with ACS, approximately one in 11 had familial hypercholesterolemia, researchers reported in The American Journal of Cardiology.
Lipid-lowering therapy intensification low among veterans after MI, revascularization
Fewer than half of veterans, most of whom were not on lipid-lowering therapy before an event, received intensified lipid-lowering therapies after an MI or elective revascularization, researchers reported.
Dual therapy for lower target LDL after stroke reduces risk for events at 5 years
An LDL target of less than 70 mg/dL with ezetimibe plus statin therapy was associated with lower risk for subsequent events after stroke/transient ischemic attack at 5 years vs. a target between 90 mg/dL and 110 mg/dL, researchers reported.
Despite recommendations, statin use ‘not ubiquitous’ in CKD with ASCVD
Overall statin use among adults with chronic kidney disease is high, yet there have been only modest increases in the use of high‐intensity statins, ezetimibe and PCSK9 inhibitors, data from a prospective 2‐year study show.
New ACC document covers lipid-lowering therapies introduced since 2018 guidelines
The American College of Cardiology issued an expert consensus decision pathway to address new lipid-lowering agents and other developments since the release of the ACC/American Heart Association cholesterol guidelines in 2018.
Statin plus ezetimibe combination ‘alternative strategy’ to doubled statin dose in ASCVD
Among adults with atherosclerotic CVD at very high risk, moderate-intensity statin plus ezetimibe combination therapy was noninferior to high-intensity statin monotherapy for major CV outcomes at 3 years, including CV death, data show.
Combination glecaprevir, pibrentasvir with ezetimibe prevents HCV in transplantation
LONDON — Combined glecaprevir and pibrentasvir with ezetimibe prevented hepatitis C infection among patients who received non-liver solid organ transplants with HCV viremic grafts, according to research.
NLA refines statin intolerance definition, management
The National Lipid Association updated its scientific statement on statin intolerance with a revised definition of statin intolerance and new guidance on how to manage patients with true or partial statin intolerance.
Lipid-lowering drugs more effective in adults with high cardiovascular risk
Zetia and proprotein convertase subtilisin/kexin type 9 inhibitors may reduce nonfatal myocardial infarction and stroke in adults with high or very high cardiovascular risk, according to findings published in The BMJ.